Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest ...

An startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and ...

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

Bumpus replaced agency veteran Janet Woodcock as principal deputy commissioner in February 2024. She was previously the FDA’s ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Bruce Cozadd, who co-founded the company two decades ago, will step down once a successor is found. Jazz aims to complete its ...

MaaT Pharma is at the forefront of innovation in this field, striving to achieve the first-ever approval of a ...

A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...